Clinical trial · Interventional
Allogeneic Tumor Cell Vaccination in Patients With Chronic Myeloid Leukemia
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): PI is no longer work at Hadassah
Summary
Brief summary (as posted)
Donors with CM will be solicited from a waiting list of patients awaiting BMT from the waiting list of MUD searches. Maximally matched donor will be searched for each eligible CML patient with a goal in mind to find other patients with CML that share both class I and class II determinants. Sharing of one class I II will be considered eligible for participation in the study. Peripheral blood and PBMC from the donors will be isolated, washed and irradiated. The cells will be injected into the consenting patients intracutaneously at 2 weeks intervals for a total of 6 injections.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Chronic Myeloid Leukemia | Chronic Myeloid Leukemia, BCR-ABL1 Positive | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Allogeneic tumor cell vaccine | Biological | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Investigate the feasibility of allogeneic tumor cell vaccine for patients with resistant CML.
Secondary outcomes (1)
- measure
- To induce immunity against a putative bcr/abl peptide bound to MHC identical class I, II or preferably both.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 55 Years
Show eligibility criteria text
Inclusion Criteria: * Patients above the age of 55 consenting to participate in the study. * Patients with documented CML with Philadelphia chromosome t (9:21) * Patients with no HLA matched sibling. * Patients eligible for BMT for who no matched unrelated donor can be identified after completion of an international donor search lasting for more than six months, or patients that have failed BMT. * Patients with contra-indication to BMT. * Patients refusing BMT. * Patients who failed interferon alpha, ARAc and/or Glivec. Exclusion Criteria: * Patients requiring immunosuppressive therapy or corticosteroids.
References
Publications (0)
Data not yet available